Protagonist Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Protagonist Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Protagonist Therapeutics Inc Strategy Report
- Understand Protagonist Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Protagonist Therapeutics Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
18 Mar 2024 | Takeda Enters into Licensing Agreement with Protagonist Therapeutics | Licensing Agreement |
Takeda Pharmaceutical Co Ltd
|
Protagonist Therapeutics Inc |
04 Apr 2023 | Protagonist Therapeutics Prices Public Offering of Shares for USD100 Million | Equity Offering | - |
Protagonist Therapeutics Inc |
01 Apr 2022 | Protagonist Therapeutics Inc Enters Phase III Clinical Trial Agreement with Medpace Holdings Inc for rusfertide acetate (GDCT0391958) | Contract Service Agreement |
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc |
Medpace Holdings Inc Medpace Holdings Inc Medpace Holdings Inc |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer